Skip to main content
NCBI home page
Journal of Cancer Research and Clinical Oncology logoLink to Journal of Cancer Research and Clinical Oncology
. 1990 Mar;116(2):197–202. doi: 10.1007/BF01612677

The therapeutic effect of OK-432-combined adoptive immunotherapy against liver metastases from breast cancer

Takashi Okino 1,✉, Norimichi Kan 1, Masaki Nakanishi 1, Kohei Satoh 1, Keiichi Mise 1, Yasufumi Teramura 1, Seiji Yamasaki 1, Taisuke Hori 1, Hiroshi Kodama 1, Kazuhisa Ohgaki 1, Takayoshi Tobe 1
PMCID: PMC12201054  PMID: 2324164

Abstract

We studied the therapeutic effect of OK-432 combined with adoptive immunotherapy in 19 cases of liver metastases from breast cancer. Of the 14 patients who received intraarterial OK-432 injection and transfer of cultured lymphocytes, 9 responded to this therapy, whereas no patients responded to intravenous administration. The minimum cell number for a therapeutic response was 8×108 cells. Metastatic lesions other than those in the liver regressed after therapy in 4 patients. The serum carcinoembryonic antigen level paralleled the therapeutic effect. There were no severe side-effects accompanying this therapy. These results indicate that intraarterial adoptive immunotherapy combined with OK-432 is effective as a new therapeutic approach against liver metastases from breast cancer.

Key words: Adoptive immunotherapy, Breast cancer, Liver metastasis, Interleukin-2, OK-432

Abbreviations

AIT

adoptive immunotherapy

CEA

carcinoembryonic antigen

HBSS

Hanks' balanced salt solution

LAK

lymphokine-activated killer

SE-Ag

sonicated tumor extract antigen

References

  1. Canellos GP, Devita VT, Gold GL, Chabner BA, Schein PS, Young RC (1976) Combination chemotherapy for advanced breast cancer: response and effect on survival. Ann Intern Med 84:389–392 [DOI] [PubMed] [Google Scholar]
  2. Chu TM, Nemoto T (1973) Evaluation of carcinoembryonic antigen in human mammary carcinoma. J Natl Cancer Inst 51:1119–1122 [DOI] [PubMed] [Google Scholar]
  3. George SL, Hoogstraten B (1978) Prognostic factors in the initial response to therapy by patients with advanced breast cancer. J Natl Cancer Inst 60:731–736 [DOI] [PubMed] [Google Scholar]
  4. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155:1823–1841 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Haagensen DE, Kister SJ, Panick J, Giannola J, Hansen HJ, Wells SA Jr (1978) Comparative evaluation of carcinoembryonic antigen and gross cystic disease fluid protein as plasma markers for human breast carcinoma. Cancer 42:1646–1652 [DOI] [PubMed] [Google Scholar]
  6. Hori T, Kan N, Nio Y, Tsuchitani T, Inamoto T, Kodama H, Tobe T (1986) Augmentation by OK-432 of cytotoxic activities of lymphocytes in carcinomatous pleural effusions and its application for adoptive immunotherapy. In: Tobe T (eds) New application of OK-432. Excerpta Medica, Tokyo, pp 132–140 [Google Scholar]
  7. Inamoto T, Ohgaki K, Hikasa Y, Kodama H (1984) Specific antitumor immunity in pre- and postoperative state and five year survival of breast cancer patients. Arch Jpn Chir 53:345–352 [PubMed] [Google Scholar]
  8. Jones SE, Durie BGM, Salmon SE (1975) Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer. Cancer 36:90–97 [DOI] [PubMed] [Google Scholar]
  9. Kan N, Ohgaki K, Yamasaki N, Hori T, Nakayama N, Nio Y, Inamoto T, Hikasa Y (1983) Cancer immunotherapy by local transfer of autologous T lymphocytes cultured with T cell growth factor and autologous tumor extract. Arch Jpn Chir 52:841–853 [PubMed] [Google Scholar]
  10. Kan N, Ohgaki K, Inamoto T, Kodama H (1984) Anti-tumor and therapeutic effects of spleen cells from tumor-bearing mice cultured with T cell growth factor and soluble tumor extract. Cancer Immunol Immunother 18:215–222 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kan N, Okino T, Kodama H, Ohgaki K, Tobe T, Inamoto T (1987) Breast cancer-specific immunity evaluated by a new in vitro method: IL2 enhanced MLTR. J Jpn Surg Soc 88:1624–1631 [PubMed] [Google Scholar]
  12. Kan N, Ohgaki K, Okino T, Nakanishi M, Nio Y, Inoue K, Tobe T (1988) Immunotherapy of gastric cancer. Jpn J Cancer Chemother 15:755–762 [PubMed] [Google Scholar]
  13. Kan N, Okino T, Nakanishi M, Satoh K, Mise K, Yamasaki S, Teramura Y, Ohgaki K, Tobe T (1990) Therapeutic efficacy of sequential therapy with OK-432, cyclophosphamide, IL2-cultured lymphocytes and in vivo IL2 against advanced murine plasmacytoma. Biotherapy (in press) [DOI] [PubMed]
  14. Nakanishi M, Kan N, Okino T, Satoh K, Mise K, Teramura Y, Yamasaki S, Ohgaki K, Tobe T (1990) Comparison between crude interleukin-2 and recombinant interlcukin-2 in maintaining killing activity of cultured lymphocytes. Biotherapy (in press) [DOI] [PubMed]
  15. Nio Y, Tsuchitani T, Ohgaki K, Inamoto T, Kan N, Tobe T (1986) Effects of oral administration of the streptococcal preparation OK-432 (Picibanil) on natural killer cell activity and lymphoproliferative response in mice with transplanted cecal tumors. In: Tobe T (eds) New application of OK-432. Excerpta Medica, Tokyo, pp 1–16 [Google Scholar]
  16. Okamoto H, Monami M, Shoin S, Koshimura S, Shimizu R (1966) Experimental anticancer studies part 31. On the streptococcal preparation having potent anticancer activity. Jpn J Exp Med 36:175–186 [PubMed] [Google Scholar]
  17. Okuno K, Takagi H, Nakamura T, Nakamura Y, Iwasa Z, Yasutomi M (1986) Treatment for unresectable hepatoma via selective hepatic arterial infusion of lymphokine-activated killer cells generated from autologous spleen cells. Cancer 58:1001–1006 [DOI] [PubMed] [Google Scholar]
  18. Peets M, Swanson J, Moseley HS, Fletcher WS (1982) Endocrine ablation and hepatic artery infusion in the treatment of metastases to the liver from carcinoma of the breast. Surg Gynecol Obstet 155:395–400 [PubMed] [Google Scholar]
  19. Powles TJ, Coombes RC, Smith IE, Jones JM, Ford HT, Gazet JC (1980) Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet 1:580–582 [DOI] [PubMed] [Google Scholar]
  20. Rosenberg SA, Lotze MT, Muul LN, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin 2 or high-dose interleukin 2 alone. N Engl J Med 316:889–897 [DOI] [PubMed] [Google Scholar]
  21. Russel JA, Baker JW, Dady PJ, Ford HT, Gazet JC, McKinna JA, Nash AG, Powles TJ (1978) Combination chemotherapy of metastatic breast cancer with vincristine, adriamycin and prednisolone. Cancer 41:396–399 [DOI] [PubMed] [Google Scholar]
  22. Santi L, Civalleri D, Conte PF, Fraschini G, Sertoni MR (1985) Regional intra-arterial chemotherapy of metastatic liver cancer. Chemioterapia 9:359–368 [PubMed] [Google Scholar]
  23. World Health Organization (1976) WHO handbook for reporting results of cancer treatment (Offset publication no 25), WHO, Geneva [Google Scholar]
  24. Zinser JW, Hortobagyi GN, Buzdar AU, Smith TL, Fraschini G (1987) Clinical course of breast cancer patients with liver metastases. J Clin Oncol 5:773–782 [DOI] [PubMed] [Google Scholar]

Articles from Journal of Cancer Research and Clinical Oncology are provided here courtesy of Springer

RESOURCES